An Open-Label Expanded Access Trial for Bendamustine HCl in Patients With Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia.

Trial Profile

An Open-Label Expanded Access Trial for Bendamustine HCl in Patients With Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Bendamustine (Primary)
  • Indications B cell lymphoma; Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Expanded access; Registrational
  • Acronyms BENDACT
  • Sponsors Lundbeck Inc
  • Most Recent Events

    • 18 Sep 2013 Actual end date changed from 1 Sep 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.
    • 12 Mar 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 01 Mar 2012 Planned initiation date changed from 1 Feb 2012 to 1 Mar 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top